期刊文献+

利奈唑胺群体药动学的文献分析 被引量:5

Research progress of linezolid in population pharmacokinetics
下载PDF
导出
摘要 利奈唑胺是临床常用的抗革兰氏阳性菌感染药物,其个体间药动学差异大。本文通过查阅当前发表的利奈唑胺群体药动学文献,提取建模相关信息并进行分析归纳与综述,以期为利奈唑胺的临床用药提供参考。相关文献表明利奈唑胺代谢的主要影响因素为体重、年龄、肌酐清除率和肾小球滤过率,临床制订给药方案时应优先考虑这些因素。 Linezolid is a commonly used anti gram-positive bacterial infection drug,with different pharmacokinetics.In this paper,currently published literatures about population pharmacokinetic of linezolid were reviewed,and the information related to the modeling was extracted,analyzed and summarized to provide reference for the use of linezolid.The main influencing factors of linezolid metabolism were body weight,age,creatinine clearance rate and glomerular filtration rate.These factors should be considered in the optimization of clinical dosing regimen.
作者 陈杏凯 张海霞 CHEN Xing-kai;ZHANG Hai-xia(Department of Pharmacy,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008;Nanjing Medical Center for Clinical Pharmacy,Nanning 210008)
出处 《中南药学》 CAS 2021年第1期158-161,共4页 Central South Pharmacy
关键词 利奈唑胺 群体药动学 影响因素 linezolid population pharmacokinetic influencing factor
  • 相关文献

参考文献2

二级参考文献11

  • 1Mensa J, Barberan J, Llinares P, et al. [Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus][J]. Rev Esp Quimioter, 2008, 21(4): 234-258.
  • 2Yanagihara K, Kihara R, Araki N, et al. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin- resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection[J]. Int J Antimicrob Agents, 2009, 34(5): 477-481.
  • 3Coban AY, Bilgin K, Uzun M, et al. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates][J]. Mikrobiyol Bul, 2009, 43(2): 293-297.
  • 4Stolle LB, Plock N, Joukhadar C, et al. Pharmacokinetics of linezolid in bone tissue investigated by in vivo microdialysis[J]. Scand J Infect Dis, 2008, 40(1): 24-29.
  • 5Kosaka T, Kokufu T, Shime N, et al. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients[J]. Int J Antimicrob Agents, 2009, 33(4): 368-370.
  • 6Tsuji Y, Hiraki Y, Mizoguchi A, et al. Pharmaeokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure[J]. J Infect Chemother, 2008, 14(2): 156-160.
  • 7Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion[J]. Int J Antimicrob Agents, 2008, 31(2): 122-129.
  • 8Strukova EN, Smirnova MV, Vostrov SN, et al. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model[J]. Int J Antimicrob Agents, 2009, 33(3): 251-254.
  • 9Allen GP, Bierman BC. In vitro analysis of resistance selection by linezolid in vaneomycin-susceptible and - resistant Enterococcus faecalis and Enterococcus faecium[J]. Int J Antimicrob Agents, 2009, 34(1): 21-24.
  • 10Abe S, Chiba K, Cirincione B, et al. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients[J]. J Clin Pharmacol, 2009, 49(9): 1071-1078.

共引文献14

同被引文献55

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部